Skip to content

Current ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.4×+0.1×
Pfizer logo
PfizerPFE
1.2×0.0×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
+0.4×
Incyte logo
IncyteINCY
3.7×+1.6×
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
5.8×+0.3×
Disc Medicine logo
Disc MedicineIRON
24×-13.6×

Other financials

Income statement

See full
Revenue$20.7M+138%
Gross profit$19.4M+154%
Operating income-$110.0M-3.2%
Net income-$99.1M-11.0%
EPS (diluted)-$1.69-9.0%

Balance sheet

See full
Cash & equivalents$113.6M+43.9%
Total debt$35.7M-32.5%
Total equity$1.1B-24.4%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow-$118.9M-6.7%
CapEx$769.0K+0.4%
Free cash flow-$119.7M-6.6%

Valuation

See full
Market cap$2.12B+18.1%
Enterprise value$2.04B+15.2%
P/S32.1×-16.4×

Profitability

See full
Gross margin90%+2.5pp
Operating margin-720%-204pp
Net margin-639.8%
FCF margin-582.5%-185pp

Returns & leverage

See full
Return on equity-32.8%
Debt / equity0.0×

Where this comes from

Calculated from Agios Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Agios Pharmaceuticals's current ratio?
Agios Pharmaceuticals (AGIO) reported current ratio of 14.2× in Q1 2026.
How has Agios Pharmaceuticals's current ratio changed year-over-year?
Agios Pharmaceuticals's current ratio decreased by 23.3% year-over-year, from 18.5× to 14.2×.
What is the long-term trend for Agios Pharmaceuticals's current ratio?
Over 5 years (2020 to 2025), Agios Pharmaceuticals's current ratio has grown at a 11.2% compound annual growth rate (CAGR), from 6.7× to 11.5×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.